Were we prepared for PrEP? Five years of implementation

While the overall incidence of HIV infections in the United States (US) has decreased in recent years, certain populations remain particularly vulnerable, including racial/ethnic minorities, adolescents/young adults, and people in the southern US [1]. The Centers for Disease Control and Prevention (CDC) stated strategy to combat new infections includes a combination of “cost-effective, scalable interventions based on current science” [2]. In July 2012, the US Food and Drug Administration (FDA) approved daily oral combination tenofovir/emtricitabine (“Truvada”) for pre-exposure prophylaxis (PrEP) in at-risk uninfected adults, with subsequent endorsement as blanket policy by the CDC in May 2014 [3].